Latest Rafarma Pharmaceuticals Inc. (RAFA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Latest Rafarma Pharmaceuticals Inc. [Wy] (RAFA) Headlines

Rafarma Pharmaceuticals (OTC:RAFA) Announces Cooperative Agreement with the St. Petersburg Academy of Pharmaceutical Chemistry
PR Newswire - Wed Feb 05, 7:00AM CST
On February 3, 2014, ZAO Rafarma management met with senior faculty members of the St. Petersburg Academy of Pharmaceutical Chemistry to create a long-term cooperative agreement.

Governor's Initiative Paves Way For Pharmaceutical Joint Venture Between Rafarma Pharmaceuticals And St. Petersburg-Based Pharmsynthez
PR Newswire - Tue Jan 28, 10:02AM CST
Rafarma Pharmaceuticals (OTC:RAFA) and St. Petersburg-based Pharmsynthez have opened discussions for Joint Venture Production.

Rafarma Pharmaceuticals Announces a $1.2 Million Private Placement
PR Newswire - Thu Dec 12, 3:05PM CST
Rafarma Pharmaceuticals (OTC:RAFA), announces a $1.2 million private placement.

Rafarma Pharmaceuticals, Inc. (RAFA) Joins in Economic Development Coalition to Increase Biotech Growth in Terbuny, Russia.
PR Newswire - Mon Nov 11, 8:35AM CST
Executive leadership at Rafarma Pharmaceuticals (OTC:RAFA), recently met with the Governor of Lipetsk, Oleg Korolev, along with several government economic development representatives, including the Trade mission of the Russian Federation in Great Britain and announced plans for British investment in the region to create a "biopharmaceutical cluster" in Terbuny. The parties signed a project initiative to increase growth of the pharmaceutical industry in the region, finalize British investment and obtain manufacturing contracts for Rafarma and its biotech neighbors. As a certified and operating pharmaceutical manufacturer, Rafarma will be the lead company in this venture.

Rafarma Pharmaceuticals, Inc. (RAFA) announces plans for PCAOB-Registrant Audit and Streamlining of Corporate Structure to Upgrade Market Listing.
PR Newswire - Thu Sep 19, 8:15AM CDT
Rafarma Pharmaceuticals (OTC:RAFA), in an effort to upgrade its market listing has announced plans for a full audit and a streamlining of its corporate structure.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters New Distribution Agreement with Amber Pharma Distribution Group
PR Newswire - Tue Sep 10, 8:05AM CDT
Rafarma Pharmaceuticals, Inc., OTC symbol "RAFA," announced it has entered into a new multi-year distribution contract with Amber Pharma Distribution Group, a boutique international business development firm. The principals of Amber Pharma have more than 75 years of combined international business development experience in a wide range of industry sectors including pharmaceuticals, finance, software, telecommunications and trade. It is intended that this new alliance with Rafarma will lead to over $100 million USD in new sales within the next 24 to 36 months.

Rafarma Pharmaceuticals, Inc. (RAFA) New Dialysis Research and Development Center to Join Rafarma in Making Terbuny Russia's New Biotech Hub
Marketwire - Fri Aug 02, 10:10AM CDT
The success of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) in choosing Terbuny for its facility has attracted more biotech companies to the area. A new facility specifically devoted to dialysis research and product development has been announced.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Cooperative Effort With Christian Albrecht University in Kiel, Germany
Marketwire - Thu Jul 25, 8:40AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces a cooperative research and development effort with Christian Albrecht University in Kiel on the following projects:

Rafarma Pharmaceuticals, Inc. (RAFA) Operational Subsidiary Introduces New Board of Directors
Marketwire - Wed Jul 17, 9:08AM CDT
The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Exclusive Production Contract With JSC F-Synthesis to Produce Anti-Cancer Drug Imatinib
Marketwire - Tue Jul 16, 12:48PM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) announces the signing of a new exclusive production agreement with JSC F-Synthesis for the production of the anti-cancer drug Imatinib.

Rafarma Pharmaceuticals, Inc. (RAFA) Enters Into New Production Contract for Para-Aminosalicylic Acid
Marketwire - Fri Jul 05, 9:28AM CDT
Rafarma Pharmaceuticals, Inc. (OTC: RAFA) is pleased to announce that in June of this year the Company entered into a production agreement to manufacture Para-Aminosalicylic Acid (PAS) to be marketed and distributed by OOO "Advance Trading," which is one of the leading distributors of PAS in Russia.

Rafarma (RAFA) Enters $50,000,000 Ceftriaxone Market and Signs Long-Term National and Regional Distribution Contracts
GlobeNewswire - Thu Jun 06, 8:18AM CDT
Rafarma Pharmaceuticals, Inc. (the "Company") (Pink Sheets:RAFA) announces commencement of production of the antibiotic Ceftriaxone.

Rafarma Pharmaceuticals, Inc. (RAFA) Announces Engagement of QualityStocks Investor Relations Services
Marketwire - Wed Apr 10, 7:00AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA) announces today that they have agreed with QualityStocks to be featured in The Small Cap QualityStocks Daily Newsletter, QualityStocks Daily Blogs and Message Boards. QualityStocks, based in Scottsdale, Arizona, is a free service that collates data from hundreds of Small-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts.

Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Marketwire - Mon Apr 08, 7:02AM CDT
Rafarma Pharmaceuticals, Inc. (PINKSHEETS: RAFA), a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products, today announces that ZAO "Rafarma" has registered (MHH) CEFTRIAXONE, a third-generation cephalosporin antibiotic, as a medication under international unpatented label.

Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
PR Newswire - Mon Feb 04, 8:15AM CST
Rafarma Pharmaceuticals, Inc. (the "Company") OTC symbol (RAFA) announced that it has received the general license for pharmaceutical products and has started the manufacturing of 3 new products. The general license was one of the final steps required to open the new plant in Terbuniy. The Company is now in operation and is expected to rapidly increase to 100% capacity of the Terbiniy facility with the addition of government contracts provided by being 1 of 4 National Strategic Pharmaceutical Suppliers to the Russian Federation.

Rafarma Pharmaceuticals, Inc. (WY) (RAFA) Stock Research Links

RAFA Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 514

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 527

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 391

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 90

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 225

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading